Celgene: S&P 5-star buy in biotech

---

by Steven Silver, equity analyst Standard & Poor’s The Outlook

S&P Capital IQ considers Celgene (CELG) to be one of the biotechnology stocks best positioned for long-term growth, with solid core product growth, an advancing new product pipeline, and a strong financial position.

We expect Celgene to deliver earnings growth at a compound annual rate of 21% from 2010 through 2013, driven by expanding sales of its key cancer drug Revlimid. This figure represents the brightest growth prospects we see in the large-cap biotech industry.